Mathew Simcock

1.8k total citations
46 papers, 926 citations indexed

About

Mathew Simcock is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Mathew Simcock has authored 46 papers receiving a total of 926 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 17 papers in Oncology and 13 papers in Hematology. Recurrent topics in Mathew Simcock's work include Multiple Myeloma Research and Treatments (9 papers), Protein Degradation and Inhibitors (7 papers) and Head and Neck Cancer Studies (7 papers). Mathew Simcock is often cited by papers focused on Multiple Myeloma Research and Treatments (9 papers), Protein Degradation and Inhibitors (7 papers) and Head and Neck Cancer Studies (7 papers). Mathew Simcock collaborates with scholars based in Switzerland, Italy and United States. Mathew Simcock's co-authors include Daniel M. Aebersold, Jakob Passweg, Pirus Ghadjar, Ursula Flückiger, Parham Sendi, Manuel Battegay, Aristoteles Giagounidis, Gert J. Ossenkoppele, Arnold Ganser and Carlo Aul and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Mathew Simcock

45 papers receiving 903 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mathew Simcock Switzerland	18	272	214	188	178	164	46	926
Reggie Duerst United States	17	213 0.8×	96 0.4×	85 0.5×	46 0.3×	414 2.5×	42	902
Cindy McGrath United States	21	356 1.3×	175 0.8×	461 2.5×	76 0.4×	121 0.7×	45	1.4k
S Andresen United States	19	442 1.6×	145 0.7×	88 0.5×	84 0.5×	620 3.8×	35	998
A Schattenberg Netherlands	20	516 1.9×	85 0.4×	181 1.0×	117 0.7×	785 4.8×	35	1.3k
Alva B. Weir United States	13	280 1.0×	77 0.4×	158 0.8×	33 0.2×	122 0.7×	43	941
Glen Kennedy Australia	21	385 1.4×	170 0.8×	222 1.2×	73 0.4×	483 2.9×	115	1.4k
M Kalaycio United States	24	626 2.3×	235 1.1×	224 1.2×	146 0.8×	980 6.0×	76	1.8k
A Grañena Spain	15	356 1.3×	162 0.8×	124 0.7×	53 0.3×	517 3.2×	46	956
Rasim Gucalp United States	24	1.1k 4.0×	269 1.3×	187 1.0×	128 0.7×	193 1.2×	87	1.7k
Mauricette Michallet France	19	266 1.0×	86 0.4×	269 1.4×	229 1.3×	484 3.0×	73	1.2k

Countries citing papers authored by Mathew Simcock

Since Specialization

Citations

This map shows the geographic impact of Mathew Simcock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mathew Simcock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mathew Simcock more than expected).

Fields of papers citing papers by Mathew Simcock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mathew Simcock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mathew Simcock. The network helps show where Mathew Simcock may publish in the future.

Co-authorship network of co-authors of Mathew Simcock

This figure shows the co-authorship network connecting the top 25 collaborators of Mathew Simcock. A scholar is included among the top collaborators of Mathew Simcock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mathew Simcock. Mathew Simcock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Locatelli, Franco, Irene Schmid, Julián Sevilla, et al.. (2024). Efficacy and safety of azacitidine in pediatric patients with newly diagnosed advanced myelodysplastic syndromes before hematopoietic stem cell transplantation in the AZA‐JMML‐001 trial. Pediatric Blood & Cancer. 71(5). e30931–e30931. 1 indexed citations

Fangusaro, Jason, Maria Giuseppina Cefalo, Maria Luisa Garrè, et al.. (2021). Phase 2 Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors. Frontiers in Oncology. 11. 660892–660892. 6 indexed citations

Amoroso, Loredana, Victoria Castel, Gianni Bisogno, et al.. (2020). Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network. European Journal of Cancer. 135. 89–97. 15 indexed citations

Reinhardt, Dirk, Henrik Hasle, Karsten Nysom, et al.. (2020). Efficacy, Safety, and Pharmacokinetics (PK) of Azacitidine (AZA) in Children and Young Adults with Acute Myeloid Leukemia (AML) in the Phase 2 AZA-AML-004 Trial. Blood. 136(Supplement 1). 10–11. 1 indexed citations

Palumbo, Antonio, Philippe Moreau, Meletios Α. Dimopoulos, et al.. (2015). OUTCOMES FOR OLDER PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN THE STRATUS (MM-010) TRIAL, A SINGLE-ARM, PHASE 3B STUDY. Haematologica. 100. 82–83. 1 indexed citations

Dimopoulos, Meletios Α., Antonio Palumbo, Paolo Corradini, et al.. (2015). THE STRATUS (MM-010) TRIAL: A SINGLE-ARM, PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA. Haematologica. 100. 83–83. 1 indexed citations

Belloni, Benedetta, et al.. (2014). Clinical implications of distinct metastasizing preferences of different melanoma subtypes. European Journal of Dermatology. 24(2). 236–241. 13 indexed citations

Schraml, Peter, Adriana von Teichman, Daniela Mihic‐Probst, et al.. (2012). Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Oncology Reports. 28(2). 654–658. 26 indexed citations

Ghadjar, Pirus, Mathew Simcock, Frank Zimmermann, et al.. (2012). Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94). Radiotherapy and Oncology. 104(2). 213–218. 25 indexed citations

10.

Früh, Martin, Richard Cathomas, Marco Siano, et al.. (2012). Carboplatin and Paclitaxel Plus ASA404 as First-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Multicenter Single Arm Phase II Trial (SAKK 15/08). Clinical Lung Cancer. 14(1). 34–39. 22 indexed citations

11.

Moos, Roger von, Burkhardt Seifert, Mathew Simcock, et al.. (2011). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Annals of Oncology. 23(2). 531–536. 54 indexed citations

12.

Ghadjar, Pirus, Mathew Simcock, Gabriela Studer, et al.. (2011). Concomitant Cisplatin and Hyperfractionated Radiotherapy in Locally Advanced Head and Neck Cancer: 10-Year Follow-Up of a Randomized Phase III Trial (SAKK 10/94). International Journal of Radiation Oncology*Biology*Physics. 82(2). 524–531. 31 indexed citations

13.

Ghadjar, Pirus, Beat Bojaxhiu, Mathew Simcock, et al.. (2011). High Dose-Rate Versus Low Dose-Rate Brachytherapy for Lip Cancer. International Journal of Radiation Oncology*Biology*Physics. 83(4). 1205–1212. 37 indexed citations

14.

Zaman, Khalil, Beat Thürlimann, Jens Huober, et al.. (2011). Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Annals of Oncology. 23(6). 1474–1481. 32 indexed citations

15.

Moos, Roger von, Arnaud Roth, Thomas Ruhstaller, et al.. (2010). Oxaliplatin, Irinotecan and Capecitabine (OCX) for First-Line Treatment of Advanced/Metastatic Colorectal Cancer: A Phase I Trial (SAKK 41/03). Onkologie. 33(6). 295–299. 3 indexed citations

16.

Dummer, Reinhard, Olivier Michielin, Burkhardt Seifert, et al.. (2010). First-line temozolomide (TEM) combined with bevacizumab (BEV) in metastatic melanoma (MM): A multicenter phase II trial (SAKK 50/07).. Journal of Clinical Oncology. 28(15_suppl). 8521–8521. 4 indexed citations

17.

Ghadjar, Pirus, Mathew Simcock, Ivan Hegyi, et al.. (2009). MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers. Clinical & Experimental Metastasis. 26(7). 809–815. 30 indexed citations

18.

Hitz, Felicitas, Giovanni Martinelli, Emanuele Zucca, et al.. (2009). A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03. Hematological Oncology. 27(3). 154–159. 6 indexed citations

19.

Simcock, Mathew, Parham Sendi, Andreas F. Widmer, et al.. (2007). Empirical use of antibiotics and adjustment of empirical antibiotic therapies in a university hospital: a prospective observational study. BMC Infectious Diseases. 7(1). 21–21. 49 indexed citations

20.

Sendi, Parham, Huldrych F. Günthard, Mathew Simcock, et al.. (2007). Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure. PLoS ONE. 2(1). e173–e173. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact